Monkey IL-1a ELISA Kit

Product details

Monkey IL-1a ELISA Kit (ab269550) is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of IL-1a protein in edta plasma, hep plasma, serum, and cit plasma. It uses our proprietary SimpleStep ELISA® technology. Quantitate Monkey IL-1a with 12.21 pg/ml sensitivity.

SimpleStep ELISA® technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details. Our SimpleStep ELISA® technology provides several benefits:

- Single-wash protocol reduces assay time to 90 minutes or less
- High sensitivity, specificity and reproducibility from superior antibodies
- Fully validated in biological samples
- 96-wells plate breakable into 12 x 8 wells strips

A 384-well SimpleStep ELISA® microplate (ab203359) is available to use as an alternative to the 96-well microplate provided with SimpleStep ELISA® kits.

Signaling of IL-1 via its receptor, results in recruitment of the IL-1 R accessory protein (IL-1RAcP). This leads to a series of phosphorylation and ubiquitination events that ultimately activate the nuclear factor ĸB (NF-ĸB) and signal via the c-Jun N-terminal kinase (JNK) and the p38 mitogen-activated protein kinase (MAPK) pathways. These signaling events generate local and systemic responses that mediate acute phase inflammation, a critical host response to injury and infection. Under these circumstances, IL-1 induces fever, pain sensitivity, vasodilation, hypotension and slow wave sleep. All these responses are essential processes geared towards the re-establishment of tissue homeostasis. However, prolonged and inappropriate IL-1 induction has been shown to be associated with sepsis, rheumatoid arthritis, inflammatory bowel disease, acute and chronic myelogenous leukemia, insulin-dependent diabetes mellitus and atherosclerosis.